Skip to main content

Table 2 Basic demographic characteristics of enrolled CKD patients

From: Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

  No-KA KA p value
(n = 175) (n = 148)
CKD stage
3 123 (0.703) 78 (0.527) 0.000
4 42 (0.240) 42 (0.284)
5 10 (0.057) 28 (0.189)
Gender
Man 108 (0.62) 78 (0.52) 0.114
Woman 67 (0.38) 70 (0.48)
Age (year) 46.7 ± 12.6 46.0 ± 11.7 0.601
Education
Primary 26 (0.15) 25 (0.17) 0.030
Secondary 96 (0.55) 97 (0.66)
Higher 53 (0.30) 26 (0.16)
Occupation
Manual worker 17 (0.10) 30 (0.20) 0.021
Brain-worker 77 (0.44) 52 (0.35)
Unemployed/retiree 81 (0.46) 66 (0.45)
Complication
No 119 (0.68) 101 (0.68) 1.000
Yes 56 (0.32) 47 (0.32)
Smoke
No 113 (0.65) 97 (0.66) 0.793
Sometimes 5 (0.03) 3 (0.02)
Yes 57 (0.33) 43 (0.29)
Alcohol
No 123 (0.70) 107 (0.72) 0.381
Yes 52 (0.30) 36 (0.24)
  1. Italic values indicate significance of p value (p < 0.05)